

| Company | Compound | Phase | Indication & Inclusion Criteria | Locations | Clinical Trial |
|--|--|--------------|--|--|--|
| Exon Skipping | | | | | |
| Wave Life Sciences | WVE-N531 | Phase I & II | Duchenne Muscular Dystrophy 5 Years to 18 Years Amenable to skipping Exon 53 | CAN, GBR | NCT04906460 |
| Dyne Therapeutics | DYNE-251 | Phase I & II | Duchenne Muscular Dystrophy 4 Years to 16 Years Amenable to skipping Exon 51 | USA (CA, CO, GA, MA, OH, UT, VA) BEL, CAN, ESP, GBR | NCT05524883 (DELIVER) |
| Avidity Biosciences | AOC 1044 | Phase I & II | Duchenne Muscular Dystrophy 7 Years to 27 Years Amenable to skipping Exon 44 | USA (CA, GA, MA, OH, TX) | NCT05670730 (EXPLORE44) |
| PepGen | CONNECT1-EDO51 | Phase II | Duchenne Muscular Dystrophy 8 Years and up Amenable to skipping Exon 51 | CAN | NCT06079736 (CONNECT1-EDO51) |
| NS Pharma Nippon Shinyaku | NS-089/ NCNP-02-201 | Phase II | Duchenne Muscular Dystrophy 4 Years to 15 years Ambulatory Amenable to exon 44 skipping | USA (CO, GA, IL, KS, OH, OR, PA, TX, VA) | NCT05996003 |
| NS Pharma Nippon Shinyaku | NS-050/NCNP-03 | Phase I & II | Duchenne Muscular Dystrophy 4 Years to 15 years Ambulatory Amenable to exon 50 skipping | TBD | NCT06053814 (Meteor50) |
| Gene Therapy | | | | | |
| Sarepta Therapeutics | SRP-9001 (Delandistrogene Moxeparovec) | Phase III | Duchenne Muscular Dystrophy Non-ambulatory or Ambulatory 8 Years to 18 Years | USA (AR, CA, FL, IL, IA, MO, NY, NC, PA, VA) | NCT05881408 (ENVISION) |
| RegenexBio | RGX-202 | Phase I & II | Duchenne Muscular Dystrophy 4 Years to 11 Years Ambulatory Mutation in Exons 18 and above | USA (CA, AR, IL) | NCT05693142 (AFFINITY DUCHENNE) |
| Roche | Delandistrogene Moxeparovec | Phase II | Duchenne Muscular Dystrophy Up to 4 Years Mutation between Exons 18 and 79 | ESP | NCT06128564 (ENVOL) |

| | | | | | |
|--|--------------|--------------|--|---|---|
| Solid Biosciences | SGT-003 | Phase I & II | Duchenne Muscular Dystrophy 4 Years to 8 Years Ambulatory | USA (CA, OH) | NCT06138639 (INSPIRE DUCHENNE) |
| Muscle Stabilizer | | | | | |
| Edgewise Therapeutics | EDG-5506 | Phase II | Duchenne Muscular Dystrophy 4 Years to 9 Years Ambulatory | USA (AR, CA, CO, FL, GA, IA, KS, MA, MD, MO, OH, TX) | NCT05540860 (LYNX) |
| Edgewise Therapeutics | EDG-5506 | Phase II | Becker Muscular Dystrophy 12 Years to 50 Years Ambulatory | USA (AR, CA, CO, IA, KS, MD, MA, MO, OH, VA) NED, GBR | NCT05291091 (GRAND CANYON) |
| Edgewise Therapeutics | EDG-5506 | Phase II | Duchenne Muscular Dystrophy 6 Years to 14 Years Ambulatory Previous treated with an AAV-based gene therapy | USA (CA, FL, MA, MO, NC, OH) | NCT06100887 (FOX) |
| Cell Therapy | | | | | |
| Capricor | CAP-1002 | Phase III | Duchenne Muscular Dystrophy 10 Years and older | USA (AR, AZ, CA, CO, GA, IA, IL, MA, MI, OH, TX, UT, VA, WA, WI) | NCT05126758 (HOPE-3) |
| Anti-inflammatory | | | | | |
| Taiho Pharmaceutical | TAS-205 | Phase III | Duchenne Muscular Dystrophy 5 Years and older Ambulatory | JPN | NCT04587908 (REACH-DMD) |
| ReveraGen BioPharma | Vamorolone | Phase II | Duchenne Muscular Dystrophy 2 Years to 17 Years | CAN | NCT05185622 |
| ReveraGen BioPharma | Vamorolone | Phase II | Becker Muscular Dystrophy 18 Years to 64 Years Ambulatory | USA (PA) | NCT05166109 |
| Nationwide Children's Hospital Children's Hospital of Chicago Children's Hospital Medical Center, Cincinnati | Prednisolone | Phase IV | Duchenne Muscular Dystrophy 1 Month to 30 Months | USA (IL, OH, TX, VA) | NCT05412394 |

| | | | | | |
|---|----------------------|----------------|---|--|-----------------------------|
| University of Florida U.S. Army Medical Research and Development Command | Prednisone | Phase II | Duchenne Muscular Dystrophy 5 Years to 8 Years Ambulatory | USA (FL) | NCT04322357 |
| Cardiac Function | | | | | |
| Medical University of Gdansk | Metoprolol Succinate | Phase III | Duchenne Muscular Dystrophy 8 Years to 17 Years | POL | NCT05066633 |
| Peking Union Medical College Hospital | Bisoprolol Fumarate | Phase II & III | Duchenne Muscular Dystrophy 7 Years and older | CHN | NCT03779646 |
| Cumberland Pharmaceuticals Vanderbilt University Medical Center | Ifetroban | Phase II | Duchenne Muscular Dystrophy 7 Years and older | USA (AR, CA, DC, GA, IL, IN, MD, MO, OH, TN) | NCT03340675 |